Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Endoscopic and imaging evaluations of neoadjuvant immunotherapy in patients with locally advanced colorectal cancer with dMMR/MSI-H or POLE/POLD1 mutation.

European radiology - 1 Sept 2026

Luo Yuesheng, Huang Wang, Zeng Zhen, Liu Leilei, Liu Yan, Chen Xiaoqian, Ren Wei, Zhang Jiuquan

Abstract excerpt

OBJECTIVES: In neoadjuvant immunotherapy, radiological assessment of pathological complete response (pCR) is frequently inaccurate, and atypical response patterns are occasionally observed. This study aims to investigate the diagnostic performance of new qualitative morphological changes for predicting pCR and to provide a comprehensive characterization of the imaging and endoscopic response patterns associated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to POLE gene

Share to Immunotherapy

Share to Mutation

Share to Neoadjuvant Therapy

Source

Identifiers

PMID: 42128946
DOI: 10.1007/s00330-026-12602-8

Genes

POLD1
POLE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Endoscopic and imaging evaluations of neoadjuvant immunotherapy in patients with locally advanced colorectal cancer with dMMR/MSI-H or POLE/POLD1 mutation.PMID 42128946Read ↗

Neoadjuvant Combination Immunotherapy for Colorectal Cancer: Clinical and Molecular Predictors of Pathological Complete Response and Safety AssessmentSemantic proximity Read ↗

Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of responseSemantic proximity Read ↗

[Interpretation of the updates of NCCN 2017 version 1.0 guideline for colorectal cancer].Semantic proximity Read ↗

A randomized, open, multicenter Phase II study to explore the sequential use of chemotherapy and immunotherapy in postoperative adjuvant therapy for gastric or esophagogastric junction adenocarcinoma or colorectal adenocarcinoma with radical resection of POLE/POLD1 gene mutation or dMMR/MSI-HSemantic proximity Read ↗

Colorectal medullary carcinoma: a pathological subtype with intense immune response and potential to benefit from immune checkpoint inhibitors.Semantic proximity Read ↗

Comprehensive Overview of Molecular, Imaging, and Therapeutic Challenges in Rectal Mucinous AdenocarcinomaSemantic proximity Read ↗

Non-invasive CT radiomic biomarkers predict microsatellite stability status in colorectal cancer: a multicenter validation studySemantic proximity Read ↗

ctDNA guided management of POLE mutant GI malignancies promotes exceptional responses and prolonged survival to immunotherapy.Semantic proximity Read ↗

Rectal cancer.Semantic proximity Read ↗

The Role of MSI Testing Methodology and Its Heterogeneity in Predicting Colorectal Cancer Immunotherapy ResponseSemantic proximity Read ↗

Efficacy and safety of neoadjuvant toripalimab plus chemotherapy in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma (NICE): a multicentre, single-arm, exploratory phase 2 studySemantic proximity Read ↗

Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONOSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.